CASE PRESENTATION
A 34-year-old woman presented with pelvic pain, abdominal bloating, and menometrorrhagia (ie, a condition of prolonged bleeding occurring more frequently than normal). She had no prior pregnancy but was seeking treatment from interventional radiology to relieve her symptoms for the possibility of future pregnancy. MRI confirmed the presence of uterine fibroids. Her uterine volume was 134 cm³ (8.1 X 5.8 X 5.5 cm), and she had three fibroids of significant size. The dominant intramural fibroid was 18.9 cm³ (4.0 X 3.5 X 2.6 cm) and extended up to the endometrial cavity, located in the uterine posterior wall. The two smaller fibroids were 1.9 cm³ and 0.9 cm³; one was intramural and the other was submucosal. The fibroids were enhanced after administration of paramagnetic endovenous contrast (Figure 1).

PROCEDURE DESCRIPTION
Right femoral access was established by placing a 5-F (1.67-mm) introducer sheath, followed by very selective catheterization of the uterine arteries. First, we accessed the uterine arteries with a selective 5-F (1.67-mm) uterine catheter, and then more distal access was obtained with a 2.7-F (0.9-mm) microcatheter. A pre-embolization selective arteriogram showed uterine-to-ovary anastomosis on both sides (Figures 2 and 3). Given this presentation, we chose 900-μm Embozene™ Microspheres for embolization. We used two vials, each with 2 mL of microspheres, to complete the bilateral embolization. We mixed the microspheres with 7 mL of Ultravist® 300 iodinated contrast (Bayer HealthCare LLC) in a 20-mL syringe, and we injected the microspheres with a 1-mL syringe and three-way stopcock. We performed the embolization by slowly injecting under fluoroscopic guidance. Bilateral embolization was performed to occlude the ascending branches of the uterine arteries leading to the patient’s fibroids. Then, after 5 minutes, we performed another arteriogram with a power injection of 8 mL of contrast (Ultravist 300) at a flow rate of 1.5 mL/sec and a frame of 0.5 seconds. This injection showed patency and preservation of the main uterine arteries and cervical branches.

In this case, the efficacy of Embozene™ was demonstrated by the total fibroid devascularization at 4- and 8-month follow-up and by the shrinkage of the dominant fibroid by 96% at 8 months postembolization.

Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
FOLLOW-UP AND DISCUSSION

Follow-up imaging was performed at 4 and 8 months postembolization. At 4-month follow-up, the patient reported remission of the menometrorrhagia, and her uterine volume had decreased from 134 cm$^3$ at presentation to 77 cm$^3$, a reduction of 42%. MRI showed total fibroid devascularization of the dominant intramural fibroid and a volume reduction of 73%. Further, there was no evidence of the other fibroids (Figure 4). At 8-month follow-up, the patient reported remission of menometrorrhagia and very good quality of life. Her uterine volume remained unchanged at 77 cm$^3$, but the fibroid volume further reduced to 0.7 cm$^3$, a reduction of 96% from the original 18.9 cm$^3$ (Figure 5). We conclude that uterine artery embolization by using Embozene™ Microspheres is a safe procedure. In our experience, we have never had microcatheter obstruction by using Embozene™ Microspheres. In this case, the efficacy of Embozene™ was demonstrated by the total fibroid devascularization at 4- and 8-month follow-up and by the shrinkage of the dominant fibroid by 96% at 8 months postembolization. The relief of fibroid-related clinical symptoms and better quality of life reported by the patient are further important factors of clinical efficacy.

Lindalva Bertelli Fernandes, MD
Diagnostic and Interventional Radiologist and Neuroradiologist Moinhos De Vento Hospital, Porto Alegre, Brazil
Member of the Brazilian Society of Interventional Radiological Society of Europe

Disclosures: Received no compensation for this article and is not a consultant to Boston Scientific.